Document is current
Any future updates will be listed below
-
Authors
Chia, Shi B.
Johnson, Bryan J. https://orcid.org/0000-0002-2328-3715
Hu, Junxiao
Valença-Pereira, Felipe https://orcid.org/0000-0003-2650-5528
Chadeau-Hyam, Marc https://orcid.org/0000-0001-8341-5436
Guntoro, Fernando
Montgomery, Hugh https://orcid.org/0000-0001-8797-5019
Boorgula, Meher P.
Sreekanth, Varsha
Goodspeed, Andrew
Davenport, Bennett https://orcid.org/0000-0001-8155-191X
De Dominici, Marco https://orcid.org/0000-0002-1019-1715
Zaberezhnyy, Vadym
Schleicher, Wolfgang E.
Gao, Dexiang https://orcid.org/0000-0003-3920-7060
Cadar, Andreia N. https://orcid.org/0000-0002-1304-5844
Petriz-Otaño, Lucia
Papanicolaou, Michael
Beheshti, Afshin
Baylin, Stephen B. https://orcid.org/0000-0003-3697-3798
Guarnieri, Joseph W.
Wallace, Douglas C. https://orcid.org/0000-0002-7480-8278
Costello, James C.
Bartley, Jenna M. https://orcid.org/0000-0003-0302-975X
Morrison, Thomas E. https://orcid.org/0000-0002-1811-2938
Vermeulen, Roel https://orcid.org/0000-0003-4082-8163
Aguirre-Ghiso, Julio A. https://orcid.org/0000-0002-6694-6507
Rincon, Mercedes https://orcid.org/0000-0002-6663-2225
DeGregori, James https://orcid.org/0000-0002-1287-1976
- License Information
-
More Information
Article History
Received: 3 April 2024
Accepted: 27 June 2025
First Online: 30 July 2025
Competing interests
: J.A.A.-G. is a co-founder, advisory board member and equity holder in HiberCell, a Mount Sinai spin-off that develops cancer recurrence-prevention therapies. He consults for HiberCell and Astrin Biosciences, serves as chief mission advisor for the Samuel Waxman Cancer Research Foundation and has ownership interest in patent number WO2019191115A1/ EP-3775171-B1. J.D. and M.R. are on the scientific advisory board for Mitotherapeutix. J.C.C. is a cofounder and chief scientific officer of OncoRx Insights. M.C.-H. holds shares in the O-SMOSE company and has no conflict of interest to disclose; consulting activities conducted by the company are independent of the present work. H.M. has consulted for Astra Zeneca relating to the use of monoclonal antibodies in the prevention and treatment of SARS-CoV-2 infection. All other authors declare no competing interests.
